Side Effects of ozanimod: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of ozanimod
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of ozanimod: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of ozanimod: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Ozanimod is a novel medication used to treat autoimmune diseases such as inflammatory bowel disease (IBD) and multiple sclerosis (MS). It belongs to a class of drugs known as sphingosine-1-phosphate (S1P) receptor modulators. Ozanimod is believed to work by preventing lymphocytes, a type of white blood cell involved in immune responses, from traveling from lymph nodes to the bloodstream, thereby reducing inflammation. 7 , 1 , 4

Reasons for Side Effects

Ozanimod's mechanism of action, which involves interfering with lymphocyte movement by interacting with S1P receptors, can impact immune system function and potentially lead to side effects. 5 , 1

Common Side Effects

Infections

As ozanimod suppresses the immune system, it can increase the risk of infections. 5 , 1 , 4

Liver Injury

Ozanimod has been associated with the potential for liver injury. 1

High Blood Pressure

Ozanimod can potentially cause high blood pressure. 1 , 2

Respiratory Side Effects

Respiratory side effects may occur with ozanimod use. 1

Macular Edema

Macular edema is a potential side effect of ozanimod. 1

Posterior Reversible Encephalopathy Syndrome

Ozanimod may cause posterior reversible encephalopathy syndrome. 1

Bradycardia

Bradycardia, a slow heart rate, is a potential side effect associated with ozanimod. 5

Side Effect Management

Infections

Taking preventative measures against infections is crucial while on ozanimod. Regular consultations with your doctor are recommended, and prompt medical attention should be sought for any signs of infection. 5

Liver Injury

Before starting ozanimod, it's important to have your liver function assessed. If you experience any liver abnormalities during treatment, contact your doctor immediately. 1

High Blood Pressure

Regular blood pressure monitoring is essential while taking ozanimod. Seek immediate medical advice if you experience any symptoms of high blood pressure. 1

Comparison Between Studies

Commonalities of Studies

Multiple research studies have consistently shown that ozanimod is effective in treating autoimmune diseases like inflammatory bowel disease and multiple sclerosis. 7 , 1 , 4 , 6 , 12 , 10

Moreover, the potential for ozanimod to cause side effects such as infections and liver injury has been reported across several studies. 5 , 1 , 4 , 2

Differences Between Studies

Research investigating the safety and efficacy of ozanimod has yielded varying results depending on the specific disease being studied and the research design employed. 6 , 12 , 2 , 10

Points to Note for Practical Applications

Ozanimod is a promising medication, but it's important to be aware of the potential for side effects like infections and liver injury. 5 , 1 , 4

It's crucial to adhere to your doctor's instructions and undergo regular check-ups while taking ozanimod. 5 , 1 , 4

Limitations of Current Research

There is still a lack of sufficient research on the long-term safety and efficacy of ozanimod. 6 , 12 , 10

Furthermore, research on the side effects of ozanimod remains incomplete. 6 , 12 , 10

Future Research Directions

Large-scale clinical trials are needed to thoroughly assess the long-term safety and efficacy of ozanimod. 6 , 12 , 10

Additional research is necessary to delve deeper into the side effects associated with ozanimod. 6 , 12 , 10

Conclusion

Ozanimod has shown promise as a treatment option for autoimmune diseases like inflammatory bowel disease and multiple sclerosis. 7 , 1 , 4 , 6 , 12 , 10

However, it's crucial to be aware of the potential for side effects like infections and liver injury. 5 , 1 , 4

When taking ozanimod, it's essential to follow your doctor's instructions and undergo regular check-ups. 5 , 1 , 4

Literature analysis of 12 papers
Positive Content
11
Neutral Content
0
Negative Content
1
Article Type
1
2
2
6
12
1.

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

Author: LassiterGrace, MelanconCarlie, RooneyTyler, MuratAnne-Marie, KayeJessica S, KayeAdam M, KayeRachel J, CornettElyse M, KayeAlan D, ShahRutvij J, ViswanathOmar, UritsIvan

Effective treatment
Well-tolerated
Fetal risk
Increased blood pressure
Infections
Liver injury
Macular edema
Posterior reversible encephalopathy syndrome
Respiratory effects

Ozanimod is a novel S1P receptor modulator approved for the treatment of multiple sclerosis (MS). This abstract discusses the efficacy and safety of ozanimod, highlighting its potential benefits and risks. Further research is needed to compare ozanimod with other S1P1 receptor modulators.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.

Author: ZhaoZhao, LvYang, GuZhi-Chun, MaChun-Lai, ZhongMing-Kang

Bradyarrhythmia risk
Cardiovascular AEs
Hypertension risk

This meta-analysis investigated the risk of cardiovascular adverse events (AEs) in patients with multiple sclerosis (MS) treated with sphingosine-1-phosphate receptor modulators (S1PRMs). Compared to control treatments, S1PRMs significantly increased the risk of cardiovascular AEs, particularly bradyarrhythmia and hypertension.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

3.

Update on treatment in multiple sclerosis.

Author: CallegariIlaria, DerfussTobias, GalliEdoardo

MS treatment

This review provides a comprehensive overview of currently approved therapies for multiple sclerosis (MS) and discusses emerging evidence-based strategies for initiating, monitoring, and adapting treatment regimens.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis.

Author: TongJingyi, ZouQin, ChenYongmin, LiaoXiaoping, ChenRong, MaLin, ZhangDaqi, LiQifu

MS treatment

This network meta-analysis (NMA) evaluated the efficacy and acceptability of S1P receptor modulators for treating multiple sclerosis (MS). It aimed to identify the most effective and well-tolerated treatment strategies for MS patients, providing a reliable basis for prescribing S1P drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.

Author: HemperlyAmy, SandbornWilliam J, Vande CasteeleNiels

Improved IBD symptoms
Drug interactions
Systemic side effects

This review describes the clinical pharmacology of major drugs used to treat inflammatory bowel disease (IBD). The review discusses pharmacokinetics, drug metabolism, mechanism of action, efficacy, and safety profiles of various medications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Video-Audio MediaMedia that combines video and audio. Includes movies, TV shows, and online videos.

Language : English

8.

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.

Author: ArmuzziAlessandro, CrossRaymond K, LichtensteinGary R, HouJason, DeepakParakkal, RegueiroMiguel, WolfDouglas C, AkukweLucy, AhmadHarris A, JainAnjali, KozinnMarc, WuHsiuanlin, PetersenAnnKatrin, CharlesLorna, LongMillie

Cardiovascular safety

This analysis reports the cardiovascular safety of ozanimod, an S1P receptor modulator, in patients with moderately to severely active ulcerative colitis from the phase 3 True North (TN) and open-label extension (OLE) trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER Multicentre Case Series.

Author: RibaldoneDavide Giuseppe, TestaGiulia, VerstocktBram, MolnarTamas, SavarinoEdoardo, SchmidtCarsten, VieujeanSophie, TeichNiels, MeianuCorina, JuilleratPascal, GrellierNathan, LobatonTriana

CARP treatment

Small molecules, such as JAK inhibitors and S1P receptor modulators, may represent a suitable option for chronic pouchitis refractory to multiple biologics. In a retrospective study of 15 patients, 53.3% achieved a clinical response and 40% achieved clinical remission after 3 months of treatment with JAK inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.

Author: TranJonathan Q, HartungJeffrey P, TompkinsCindy-Ann, FrohnaPaul A

The effect of food on the pharmacokinetics of ozanimod, a selective sphingosine-1-phosphate receptor modulator, was investigated in a randomized, open-label crossover trial. The study found that food did not significantly affect the absorption of ozanimod and its active metabolites.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.

Author: RadickLea, MehrStanton R

Disability improvement
MS treatment
Relapse rate reduction

This review summarizes data for newly approved and late-phase investigational agents for the treatment of multiple sclerosis (MS).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.